Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2015 1
2018 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.
Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, Taura K, Yasuchika K, Isoda H, Shibata T, Uemoto S. Yamanaka K, et al. J Gastroenterol. 2012 Mar;47(3):343-6. doi: 10.1007/s00535-011-0511-x. Epub 2011 Dec 21. J Gastroenterol. 2012. PMID: 22183859
BACKGROUND: There is no standard therapy for patients with transcatheter arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC). This study examined whether evaluating the tumor effect (TE) at 1 week after TACE was useful for predicting r …
BACKGROUND: There is no standard therapy for patients with transcatheter arterial chemoembolization (TACE)-refractory hepatocellul …
Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki T, Okudaira T, Toshimori A, Kawamura T, Yamago H, Nakahara H, Suga Y, Azemoto N, Miyata H, Miyamoto Y, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K. Hiraoka A, et al. Oncology. 2015;89(3):167-74. doi: 10.1159/000381808. Epub 2015 May 12. Oncology. 2015. PMID: 25999038
BACKGROUND/AIM: We examined tumor marker levels to assess in more detail transcatheter arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC). MATERIALS AND METHODS: We enrolled patients treated from 2000 to 2011 for HCC beyond the Milan …
BACKGROUND/AIM: We examined tumor marker levels to assess in more detail transcatheter arterial chemoembolization (TACE)-refractory …
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK. Harding JJ, et al. Cancer Chemother Pharmacol. 2018 Sep;82(3):429-440. doi: 10.1007/s00280-018-3635-3. Epub 2018 Jul 3. Cancer Chemother Pharmacol. 2018. PMID: 29971467 Free PMC article. Clinical Trial.
METHODS: This is a single-center, open-label, phase 1 trial of ADI-PEG 20 and modified FOLFOX6 (mFOLFOX6) in treatment-refractory hepatocellular carcinoma (HCC) and other advanced gastrointestinal tumors. ...
METHODS: This is a single-center, open-label, phase 1 trial of ADI-PEG 20 and modified FOLFOX6 (mFOLFOX6) in treatment-refractory …
Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Kondo S, Hagihara A, Shimizu S, Satake M, Arai Y. Iwasa S, et al. Jpn J Clin Oncol. 2011 Jun;41(6):770-5. doi: 10.1093/jjco/hyr037. Epub 2011 Apr 1. Jpn J Clin Oncol. 2011. PMID: 21459893
METHODS: We retrospectively examined the data of 84 consecutive patients with transcatheter arterial chemoembolization-refractory hepatocellular carcinoma who underwent transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin. …
METHODS: We retrospectively examined the data of 84 consecutive patients with transcatheter arterial chemoembolization-refractory …
Is hepatic resection for recurrent or persistent hepatocellular carcinoma justified?
Kishi Y, Saiura A, Yamamoto J, Koga R, Seki M, Morimura R, Yoshioka R, Kokudo N, Yamaguch T. Kishi Y, et al. Hepatogastroenterology. 2012 Oct;59(119):2255-9. doi: 10.5754/hge10505. Hepatogastroenterology. 2012. PMID: 23435140
Type of previous treatment did not influence prognosis. CONCLUSIONS: Hepatic resection for recurrent or refractory hepatocellular carcinoma is safe and achieves long survival in selected patients....
Type of previous treatment did not influence prognosis. CONCLUSIONS: Hepatic resection for recurrent or refractory hepatocellular …